AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04688632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampreloxetine <Dose B>
Description: Ampreloxetine \<Dose B> will be administered as 4 tablets of \<Dose A>
Study NCT04688632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampreloxetine Placebo
Description: Ampreloxetine Placebo will be administered as 4 tablets of placebo. The placebo tablet will match (in appearance) the ampreloxetine \<Dose A> tablet.
Study NCT04688632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampreloxetine Placebo
Description: Ampreloxetine Placebo will be administered as 4 tablets of placebo. The placebo tablet will match (in appearance) the ampreloxetine \<Dose A> tablet.
Study NCT04688632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin will be administered orally as a single tablet.
Study NCT04688632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Placebo
Description: Moxifloxacin placebo will be administered orally as a single tablet. The placebo tablet will match (in appearance) the moxifloxacin tablet.
Study NCT04688632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Moxifloxacin placebo will be administered orally as a single tablet. The placebo tablet will match (in appearance) the moxifloxacin tablet.
Study NCT05782517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supraglottic Airway Device
Description: Placement of an I-gel Supraglottic Airway Device.
Study NCT05782517 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Tube
Description: Placement of an Endotracheal Tube.
Study NCT06208501 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample for proteomic analysis
Description: Urine sample for proteomic analysis in screen visit (before renal denervation procedure).
Study NCT06208501 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ABPM
Description: ABPM in screen visit and 3 months after renal denervation procedure.
Study NCT06208501 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OBPM
Description: OBPM in screen visit and 3 months after renal denervation procedure.
Study NCT05652127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mightier
Description: Mightier is an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children ages 6-14
Study NCT05346029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Resistance training and nutritional counseling
Study NCT06728371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: 0.2mg/kg intravenous methadone given at induction
Study NCT06728371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.2mg/kg intravenous morphine given at induction
Study NCT05981846 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BIMERVAX
Description: One dose of booster vaccine
Study NCT05981846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIMERVAX
Description: One dose of booster vaccine
Study NCT05981846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIIV
Description: One dose
Study NCT05981846 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SIIV
Description: One dose
Study NCT05041400 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the strength of knee flexors and extensors
Description: Each participant will benefit from a clinical evaluation and an evaluation of the strength of knee flexors and extensors using an isokinetic dynamometer after a 10-minute warm up.
Study NCT04968496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Secure Group
Description: Weekly meals (five breakfast and five lunch meals) will be provided to all children randomized to this group to prevent the onset of summertime food insecurity
Study NCT03503058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
Study NCT03503058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis
Description: Infectious, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Challenge) administered under CQ chemoprophylaxis~Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of PfSPZ Challenge.
Study NCT03503058 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% Sodium chloride
Study NCT03503058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chloroquine chemoprophylaxis alone
Description: Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on NS Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of NS.
Study NCT05559320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ride-on-toy navigation training
Description: The training program will involve a set of activities where children will be encouraged to drive a joystick-operated ride-on-toy to navigate through their physical environment. The training will involve will involve progressively challenging multi-directional navigational games such as shape mazes, treasure hunts, relay races, and obstacle courses that will require children to use their affected arm skillfully to navigate through the courses.
Study NCT05559320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Upper extremity functional training
Description: In addition to the navigation practice, along the multi-directional courses, children will complete tasks at multiple stations that will involve both gross and fine motor activities. The goal of the training will be to use their arm for functional goal-directed tasks and games that will involve elements of reaching, grasping, in-hand manipulation, and release. We will use props such as balls, bean bags, cups, cones, and small toys to practice skills such as catching, throwing, picking up, pushing, pulling, opening, closing, etc.
Study NCT05591196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Electrical Spinal Cord Stimulation
Description: Electrical stimulation of the spinal cord using surface electrodes
Study NCT05591196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity Based Rehabilitation
Description: Exercise therapy targeting paralyzed hand and arm
Study NCT05591196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity Based Rehabilitation
Description: Exercise therapy targeting paralyzed hand and arm
Study NCT05023213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warna-Warni Waktu
Description: Six videos and eighteen reinforcer activities
Study NCT06496737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Interval Training (MIIT)
Description: Moderate-Intensity Interval Training (MIIT) is developed by university badminton coaches, three times a week for 12 weeks
Study NCT06496737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Description: High-Intensity Interval Training (HIIT) is developed by university badminton coaches, three times a week for 12 weeks
Study NCT05825053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait adaptability training
Description: Over a span of 1 year participants will receive 3 one hour, single sessions at 3, 6 and 9 months following baseline assessment, of gait adaptability training, using the C-mill (an instrumented treadmill with augmented reality). Several aspects of gait adaptability, such as obstacle avoidance, accelerating/decelerating and precision stepping, will be trained.
Study NCT05825053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise training
Description: Participants will receive tailored exercise through an online platform targeting gait adaptability. Participants are instructed to train at a minimum of 60 minutes per week, with a frequency of 2 sessions per week. Participants will be supported through tele-consultations on a monthly basis for the first 3 months and bi-monthly for the remaining time of the study. These consultations are focused on technical support, on ways to ensure training progression and to encourage adherence to the program.
Study NCT06516432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parasternal block
Description: In the case-control groups, patients with elevated serum lactate levels above 2 mmol/L and those who remained below this limit will be identified.
Study NCT06516432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Requirement of total dose regarding fentanyl
Description: In case-control groups, obtain measurement of total postoperative fentanyl requirement.
Study NCT04893161 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Belimumab
Description: All patients with SLE will be enrolled in one year and administrated belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48.
Study NCT05675163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2
Description: (K2VITAL® 1% MCT Oil)
Study NCT05675163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sunflower oil
Study NCT05675163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sunflower oil
Study NCT05207865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: rimegepant ODT 75mg daily
Study NCT05503498 — intervention group
Intervention type: OTHER
Intervention: DATA RECORDING
Description: RECORD PLASMA FIBRI LEVELS AFTER FIBRINOGEN ADMINISTRATION
Study NCT04735614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posthorax Thoraxbelt
Description: The patients will be assisted to put on the ThoraxBelt after the surgery by our research member and will be asked to keep it on except for during showering through the whole study period.
Study NCT04802200 — intervention group
Intervention type: OTHER
Intervention: Data collect
Description: Data collect following a vascular closure by MANTA
Study NCT04969289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dr. Eric Digital Health Intervention
Description: Dr. Eric is a user-informed, theory-based, digital health intervention that aims to improve adolescent male SRH. This ED-based intervention consists of two parts-an interactive, tailored app and 3 months of personalized, two-way text messaging. It is based on an evidence-based sexual health curriculum we developed using established behavioral theories, prior literature, input from key stakeholders, qualitative patient interviews, and our prior ED-based work.
Study NCT04149418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt
Description: Low-fat flavored yogurt
Study NCT04149418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control food
Description: Low-fat flavored soy pudding
Study NCT04938791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric activity
Description: Participants will do elevation of upper limbs and mantain a 90º degree flexion position in an unsupported way.
Study NCT05423418 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A244
Description: Dose of A244 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
Study NCT05423418 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B.63521
Description: Dose of B.63521 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
Study NCT05423418 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 50μg ALFQ
Description: Dose of ALFQ is 50μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
Study NCT05423418 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 100μg ALFQ
Description: Dose of ALFQ is 100μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
Study NCT05423418 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 200μg ALFQ
Description: Dose of ALFQ is 200μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
Study NCT05241301 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: one to one interviews
Description: one to one interviews to explore the perspective of family carers of older adults of Turkish and Moroccan origin in Flanders and Brussels, Belgium, concerning advance care planning (ACP)
Study NCT06100952 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment
Description: Drug: Ribostat riboflavin and sodium iodide ophthalmic solution~Device: UV-3000 ultraviolet A light source
Study NCT06100952 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and sham treatment
Description: Drug: placebo ophthalmic solution~Device: UV-3000 light source
Study NCT06051513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment with or without colistin
Description: For patients in this treatment group, colistin based therapy is used. Colistin combined with metroperan or imipenem（MIC≤8mg/L），or colistin combined with tigecycline, or colistin combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae. For patients in the control, best available treatment without colistin is uesed; Ceftazidime-avibactam, tigecycline combined with metroperan or imipenem（MIC≤8mg/L）, tigecycline combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae.
Study NCT06051513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment with or without colistin
Description: For patients in this treatment group, colistin based therapy is used. Colistin combined with metroperan or imipenem（MIC≤8mg/L），or colistin combined with tigecycline, or colistin combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae. For patients in the control, best available treatment without colistin is uesed; Ceftazidime-avibactam, tigecycline combined with metroperan or imipenem（MIC≤8mg/L）, tigecycline combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae.
Study NCT05203653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise only
Description: Participants will perform 3 sets of 8 repetitions of 7 different exercises while in a fasted state.
Study NCT05203653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise plus cool down
Description: Participants will perform 3 sets of 8 repetitions of 7 different exercises while in a fasted state followed by a 10-minute light aerobic cool down
Study NCT05676658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coherent breathing
Description: Guided audio of coherent breathing pre-recorded by trained breathwork facilitator: \~5.5bcpm (with equal inhalation/exhalation durations of \~5.5secs each) for \~10mins/day over four weeks / 28 days. Delivered remotely through audio link.
Study NCT05676658 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo coherent breathing
Description: Same audio of coherent breathing but paced at: \~12bcpm (with equal inhalation/exhalation durations of 2.5secs each) for \~10mins/day over four weeks / 28 days.
Study NCT05645198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oozfix
Description: Directly apply carboxymetyl starch (Oozfix) 5 gram evenly at the suprapancreatic surgical bed after gastrectomy
Study NCT05645198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Greenplast
Description: Directly apply Greenplast (Aprotinin 1000kIU/mL, Thrombin 500IU/mL, Fibrinogen 95mg/mL) 4 gram evenly at the suprapancreatic surgical bed after gastrectomy
Study NCT05643235 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
Description: Patients initiating BTK inhibitors will be offered the option of monitoring using the Medtronic Insertable Cardiac Monitor (ILR). The device will be implanted by a certified and credentialed electrophysiologist to enable monitoring to begin at least 24 hours prior to the first administration of the BTK inhibitor. Monitoring data will be collected prospectively until the patient withdraws consent, the device is removed, or up to 60 months
Study NCT05681858 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT coronary angiography and [12N] NH3 PET-MR
Description: Advanced coronary artery plaque analysis, myocardial ischemia and coronary flow reserve
Study NCT05623722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Ultrasound-guided erector spinae plane block is performed at thoracic (T) level 8. An 18F catheter is placed on both sides of the thoracic vertebra deep into the erector spinae, and a bolus of 20 ml of 0.375% ropivacaine is administered bilaterally. Then, a continuous infusion of 20 ml of 0.375% ropivacaine on each side is followed at a rate of 2 ml/h every 12 hours. The intervention ends on day 7 or ceases when the patient is discharged from the ICU, died, or withdrew their consent.
Study NCT05325580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium sulfate
Description: magnesium group 1g paracetamol + 20 min infusion of 2 g magnesium in 150 ml of saline serum and Placebo Group~1g paracetamol + 20 min infusion of 150 ml of saline serum
Study NCT05325580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: magnesium group 1g paracetamol + 20 min infusion of 2 g magnesium in 150 ml of saline serum and Placebo Group~1g paracetamol + 20 min infusion of 150 ml of saline serum
Study NCT04751617 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Pulmonary rehabilitation will include: early mobilization with frequent posture changes and simple exercises in bed taking into account the patient's respiratory tract. Respiratory physiotherapy will also include improving diaphragm function along with training additional respiratory muscles. Active exercises of the upper limbs will be accompanied by gradual muscle strengthening. Aerobic regeneration will be carried out by walking along the hospital corridor, stationary bike and climbing stairs. Body balance therapy in closed systems in front of the mirror will also be included. After kinesiotherapy, the session will end with a vibration massage and relaxation of the whole body. Motivational breathing training will be used every 2 hours, 7 days a week, performed independently by the patient in the ward room. The physiotherapy process will be carried out 6 times a week and lasts 30-45 minutes a day. The duration of rehabilitation depends on the patient's condition: from 7 to 14 days.
Study NCT06281509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive tests to determine the presence or absence of the palmaris longus tendon in both hands.
Description: Schaeffer's test (flexion of the wrist while the pinky and thumb are pressed against each other) Thompson's test (wrist flexion with a clenched fist) Mishra test I (wrist flexion while the examiner pushes the hand back) Mashra test II (thumb opposition while flexing the wrist)
Study NCT06281509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: A small mobile ultrasound device will be used to further asses the presence of the tendon.
Study NCT05457699 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: SBAR to PSMA-PET visible disease at maximal systemic therapy response.
Study NCT05457699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no RT
Description: no SABR, continued systemic therapy per SOC
Study NCT05325359 — intervention group
Intervention type: BEHAVIORAL
Intervention: L test
Description: It is an expanded version of the TUG and is designed to assess advanced functional ambulation with more detail available elsewhere. It is recorded when the participant gets up from the chair, walks 3 m to a cone, turns 90° to the right, continues to walk 7 m to the next cone, turns 180° left around the cone, then returns to the chair the same way. The test time is recorded, starting with the word go and ending with the participant's back touching the back of the chair.